Physician profile
Perrie Ryan
NPI 1073530432
$5,563.36
in general payments reported to CMS, 2019-2025
61 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $53.48 · 2021: $11.92 · 2022: $48.34 · 2023: $768 · 2024: $1,577 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,533 · Education: $26.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,533.33 |
| Education | $26.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $593.68 | 2019-2025 | |
| Celgene Corporation | $429.06 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $345.10 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Pfizer INC. | $297.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $286.77 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $266.63 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $251.20 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $216.42 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Amgen INC. | $210.06 | 2019-2023 | Kyprolis |
| Genentech USA, INC. | $194.97 | 2019-2025 | Polivy, Venclexta, Phesgo |
| Galvanize Therapeutics, INC | $168.60 | 2024 | Aliya System |
| Tempus Ai, INC | $150.64 | 2025 | Xt Cdx |
| Gilead Sciences, INC. | $123.06 | 2021-2025 | Trodelvy |
| Abbvie INC. | $117.87 | 2024-2025 | |
| Lilly USA, LLC | $108.68 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perrie Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.